Mechanisms of MHC-I Downregulation and Role in Immunotherapy Response
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Mechanisms of MHC-I Downregulation and Role in Immunotherapy Response
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 13, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2022-02-28
DOI
10.3389/fimmu.2022.844866
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- HLA class I loss in colorectal cancer: implications for immune escape and immunotherapy
- (2021) Per Anderson et al. Cellular & Molecular Immunology
- The MHC Class-I Transactivator NLRC5: Implications to Cancer Immunology and Potential Applications to Cancer Immunotherapy
- (2021) Akhil Shukla et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Therapeutically increasing MHC-I expression potentiates immune checkpoint blockade
- (2021) Shengqing Stan Gu et al. Cancer Discovery
- NLRC5/CITA expression correlates with efficient response to checkpoint blockade immunotherapy
- (2021) Sayuri Yoshihama et al. Scientific Reports
- B2M gene expression shapes the immune landscape of lung adenocarcinoma and determines the response to immunotherapy
- (2021) Yu Zhao et al. IMMUNOLOGY
- Deregulation of HLA-I in cancer and its central importance for immunotherapy
- (2021) Ahmet Hazini et al. Journal for ImmunoTherapy of Cancer
- Tumor mutational load, CD8+ T cells, expression of PD-L1 and HLA class I to guide immunotherapy decisions in NSCLC patients
- (2020) Daan P. Hurkmans et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Promotion on NLRC5 upregulating MHC-I expression by IFN-γ in MHC-I–deficient breast cancer cells
- (2020) Ming-Zhen Zhao et al. IMMUNOLOGIC RESEARCH
- Combining DNMT and HDAC6 inhibitors increases anti-tumor immune signaling and decreases tumor burden in ovarian cancer
- (2020) Sara Moufarrij et al. Scientific Reports
- Interferon regulatory factor 1 (IRF-1) and IRF-2 regulate PD-L1 expression in hepatocellular carcinoma (HCC) cells
- (2020) Yihe Yan et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Specificity of bispecific T cell receptors and antibodies targeting peptide-HLA
- (2020) Christopher J. Holland et al. JOURNAL OF CLINICAL INVESTIGATION
- The role of cancer-derived microRNAs in cancer immune escape
- (2020) Ming Yi et al. Journal of Hematology & Oncology
- Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I
- (2020) Keisuke Yamamoto et al. NATURE
- Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition
- (2020) Jenny H. Lee et al. Nature Communications
- MHC class I transactivator NLRC5 in host immunity, cancer and beyond
- (2020) Steven X. Cho et al. IMMUNOLOGY
- HLA Evolutionary Divergence as a Prognostic Marker for AML Patients Undergoing Allogeneic Stem Cell Transplantation
- (2020) Malte Roerden et al. Cancers
- MHC Class I Downregulation in Cancer: Underlying Mechanisms and Potential Targets for Cancer Immunotherapy
- (2020) Annelisa M. Cornel et al. Cancers
- Mechanisms of Cancer Resistance to Immunotherapy
- (2020) Rilan Bai et al. Frontiers in Oncology
- Uncoupling interferon signaling and antigen presentation to overcome immunotherapy resistance due to JAK1 loss in melanoma
- (2020) Anusha Kalbasi et al. Science Translational Medicine
- MAL2 drives immune evasion in breast cancer by suppressing tumor antigen presentation
- (2020) Yuanzhang Fang et al. JOURNAL OF CLINICAL INVESTIGATION
- HLA loss of heterozygosity-mediated discordant responses to immune checkpoint blockade in squamous cell lung cancer with renal metastasis
- (2020) Sheng Yu et al. Immunotherapy
- T-cell bispecific antibodies in node-positive breast cancer: novel therapeutic avenue for MHC class I loss variants
- (2019) M Messaoudene et al. ANNALS OF ONCOLOGY
- Pretransplant HLA typing revealed loss of heterozygosity in the major histocompatibility complex in a patient with acute myeloid leukemia
- (2019) Andrew L. Lobashevsky et al. HUMAN IMMUNOLOGY
- Phase Ib study of MIW815 (ADU-S100) in combination with spartalizumab (PDR001) in patients (pts) with advanced/metastatic solid tumors or lymphomas.
- (2019) Funda Meric-Bernstam et al. JOURNAL OF CLINICAL ONCOLOGY
- EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer
- (2019) K Hastings et al. ANNALS OF ONCOLOGY
- Elevated neoantigen levels in tumors with somatic mutations in the HLA-A, HLA-B, HLA-C and B2M genes
- (2019) Andrea Castro et al. BMC Medical Genomics
- DUX4 Suppresses MHC Class I to Promote Cancer Immune Evasion and Resistance to Checkpoint Blockade
- (2019) Guo-Liang Chew et al. DEVELOPMENTAL CELL
- Intrinsic Resistance to Immune Checkpoint Blockade in a Mismatch Repair–Deficient Colorectal Cancer
- (2019) Carino Gurjao et al. Cancer Immunology Research
- An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer
- (2019) Marian L. Burr et al. CANCER CELL
- Frequent Loss of IRF2 in Cancers Leads to Immune Evasion through Decreased MHC Class I Antigen Presentation and Increased PD-L1 Expression
- (2019) Barry A. Kriegsman et al. JOURNAL OF IMMUNOLOGY
- SMAR1 favors immunosurveillance of cancer cells by modulating calnexin and MHC I expression
- (2019) Aftab Alam et al. NEOPLASIA
- microRNA 125a Regulates MHC-I Expression on Esophageal Adenocarcinoma Cells, Associated With Suppression of Anti-tumor Immune Response and Poor Outcomes of Patients
- (2018) Luigi Mari et al. GASTROENTEROLOGY
- Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
- (2018) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cancer immunotherapy using checkpoint blockade
- (2018) Antoni Ribas et al. SCIENCE
- MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma
- (2018) Scott J. Rodig et al. Science Translational Medicine
- DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer
- (2018) Na Luo et al. Nature Communications
- Genetic Mechanisms of Immune Evasion in Colorectal Cancer
- (2018) Catherine S. Grasso et al. Cancer Discovery
- Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2
- (2018) Na Luo et al. OncoImmunology
- Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi
- (2018) Amila Suraweera et al. Frontiers in Oncology
- Nedd4 Binding Protein 1 (N4BP1) and TNFAIP3 Interacting Protein 1 (TNIP1) control MHC-1 display in neuroblastoma
- (2018) Lotte Spel et al. CANCER RESEARCH
- Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA
- (2018) K. G. Paulson et al. Nature Communications
- Topoisomerase I inhibitor, irinotecan, depletes regulatory T cells and up-regulates MHC class I and PD-L1 expression, resulting in a supra-additive antitumor effect when combined with anti-PD-L1 antibodies
- (2018) Toshiki Iwai et al. Oncotarget
- The MEK Inhibitors Trametinib and Cobimetinib Induce a Type I Interferon Response in Human Keratinocytes
- (2017) Daniela Lulli et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- The regulatory network behind MHC class I expression
- (2017) Marlieke L.M. Jongsma et al. MOLECULAR IMMUNOLOGY
- In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target
- (2017) Robert T. Manguso et al. NATURE
- Inhibiting DNA methylation activates cancer testis antigens and expression of the antigen processing and presentation machinery in colon and ovarian cancer cells
- (2017) Cornelia Siebenkäs et al. PLoS One
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy
- (2017) Diego Chowell et al. SCIENCE
- Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma
- (2017) Martin Lauss et al. Nature Communications
- Resistance to checkpoint blockade therapy through inactivation of antigen presentation
- (2017) Moshe Sade-Feldman et al. Nature Communications
- Upregulation of HLA Class I Expression on Tumor Cells by the Anti-EGFR Antibody Nimotuzumab
- (2017) Greta Garrido et al. Frontiers in Pharmacology
- Loss of tapasin in human lung and colon cancer cells and escape from tumor-associated antigen-specific CTL recognition
- (2017) Yosuke Shionoya et al. OncoImmunology
- CITA/NLRC5: A critical transcriptional regulator of MHC class I gene expression
- (2016) Isaac Downs et al. BIOFACTORS
- The urgent need to recover MHC class I in cancers for effective immunotherapy
- (2016) Federico Garrido et al. CURRENT OPINION IN IMMUNOLOGY
- TAP-independent self-peptides enhance T cell recognition of immune-escaped tumors
- (2016) Elien M. Doorduijn et al. JOURNAL OF CLINICAL INVESTIGATION
- T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer
- (2016) Eric Tran et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
- (2016) Jesse M. Zaretsky et al. NEW ENGLAND JOURNAL OF MEDICINE
- NLRC5/MHC class I transactivator is a target for immune evasion in cancer
- (2016) Sayuri Yoshihama et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Proteomic screening identifies calreticulin as a miR-27a direct target repressing MHC class I cell surface exposure in colorectal cancer
- (2016) T Colangelo et al. Cell Death & Disease
- Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
- (2016) Daniel Sanghoon Shin et al. Cancer Discovery
- Kinase Regulation of Human MHC Class I Molecule Expression on Cancer Cells
- (2016) E. J. Brea et al. Cancer Immunology Research
- Improving cancer immunotherapy with DNA methyltransferase inhibitors
- (2015) Mohammad H. Saleh et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors
- (2015) S. Loi et al. CLINICAL CANCER RESEARCH
- Immunomodulatory action of the DNA methyltransferase inhibitor SGI-110 in epithelial ovarian cancer cells and xenografts
- (2015) Pragya Srivastava et al. Epigenetics
- Calnexin is a novel sero-diagnostic marker for lung cancer
- (2015) Makoto Kobayashi et al. LUNG CANCER
- Immune evasion in cancer: Mechanistic basis and therapeutic strategies
- (2015) Dass S. Vinay et al. SEMINARS IN CANCER BIOLOGY
- STAT1-Induced HLA Class I Upregulation Enhances Immunogenicity and Clinical Response to Anti-EGFR mAb Cetuximab Therapy in HNC Patients
- (2015) R. M. Srivastava et al. Cancer Immunology Research
- Cross-presentation of cell-associated antigens by MHC class I in dendritic cell subsets
- (2015) Enric Gutiérrez-Martínez Frontiers in Immunology
- Adenovirus expressing β2-microglobulin recovers HLA class I expression and antitumor immunity by increasing T-cell recognition
- (2014) A B del Campo et al. CANCER GENE THERAPY
- Proteomic Analysis of Proteins Related to Prognosis of Lung Adenocarcinoma
- (2014) Akiko Okayama et al. JOURNAL OF PROTEOME RESEARCH
- The Dose-Dependent Tumor Targeting of Antibody-IFN Fusion Proteins Reveals an Unexpected Receptor-Trapping Mechanism In Vivo
- (2014) T. Hemmerle et al. Cancer Immunology Research
- A Role for Naturally Occurring Alleles of Endoplasmic Reticulum Aminopeptidases in Tumor Immunity and Cancer Pre-Disposition
- (2014) Efstratios Stratikos et al. Frontiers in Oncology
- Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death
- (2013) James W. Hodge et al. INTERNATIONAL JOURNAL OF CANCER
- HLA Class I Alleles Are Associated with Peptide-Binding Repertoires of Different Size, Affinity, and Immunogenicity
- (2013) S. Paul et al. JOURNAL OF IMMUNOLOGY
- The nucleotide-binding domain of NLRC5 is critical for nuclear import and transactivation activity
- (2012) Torsten B. Meissner et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Prognostic implications of human leukocyte antigen class I expression in patients who underwent surgical resection for non–small-cell lung cancer
- (2012) Takeshi Hanagiri et al. JOURNAL OF SURGICAL RESEARCH
- Pharmacology and therapeutic potential of interferons
- (2012) Peter M. George et al. PHARMACOLOGY & THERAPEUTICS
- IRF1 and NF-kB Restore MHC Class I-Restricted Tumor Antigen Processing and Presentation to Cytotoxic T Cells in Aggressive Neuroblastoma
- (2012) Silvia Lorenzi et al. PLoS One
- Expression of MHC Class I on breast cancer cells correlates inversely with HER2 expression
- (2012) Masayuki Inoue et al. OncoImmunology
- Genome-wide differential genetic profiling characterizes colorectal cancers with genetic instability and specific routes to HLA class I loss and immune escape
- (2011) Mónica Bernal et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Epidermal Growth Factor Receptor Inhibition Augments the Expression of MHC Class I and II Genes
- (2011) B. P. Pollack et al. CLINICAL CANCER RESEARCH
- Peptide transporter TAP mediates between competing antigen sources generating distinct surface MHC class I peptide repertoires
- (2011) Cláudia C. Oliveira et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- T cell recognition of HLA-A2 restricted tumor antigens is impaired by the oncogene HER2
- (2010) Kousaku Mimura et al. INTERNATIONAL JOURNAL OF CANCER
- ER quality control in the biogenesis of MHC class I molecules
- (2010) Daniel C. Chapman et al. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
- Hypermethylation of HLA class I gene is associated with HLA class I down-regulation in human gastric cancer
- (2009) Q. Ye et al. TISSUE ANTIGENS
- Pretreatment with Cisplatin Enhances E7-Specific CD8+ T-Cell-Mediated Antitumor Immunity Induced by DNA Vaccination
- (2008) C.-W. Tseng et al. CLINICAL CANCER RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started